Fig. 8: In vivo efficacy of Debio 1453 in a Staphylococcus aureus neutropenic murine thigh infection model. | Nature Communications

Fig. 8: In vivo efficacy of Debio 1453 in a Staphylococcus aureus neutropenic murine thigh infection model.

From: The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant Neisseria gonorrhoeae infection in vivo

Fig. 8

The infective strain, S. aureus ATCC 29213, was inoculated 2 h before the start of treatment (0 h). Thighs were harvested at 24 h and 48 h for colony-forming unit (CFU) determinations. Data are summarised by the mean for each group (black horizontal bars, n = 5 animals per group). Debio 1453 was dosed as Debio 1453 P; doses are Debio 1453 equivalents. Debio 1453 P was dosed orally, twice daily. Linezolid was dosed orally three times daily. The dotted grey lines depict the mean CFU/mL at the start of treatment. Statistically significant differences compared to 0 h were determined using one-way ANOVA with Dunnett’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001. MIC, minimum inhibitory concentration. Source data, including statistical test output with exact P-values, are provided as a Source Data file.

Back to article page